Organogenesis Holdings (ORGO)
NASDAQ:ORGO
Want to see ORGO full AI Analyst Report?
Top Page
Organogenesis Holdings
(NASDAQ:ORGO)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.50
▼(-38.73% Downside)
Action:Reiterated
Date:06/17/26
ORGO scores lower primarily due to sharply weakened profitability and a materially reduced 2026 outlook, alongside weak technical trends. Balance-sheet flexibility (including no debt cited on the call) and improving TTM free cash flow provide some support, but valuation is not compelling given negative earnings and no dividend yield provided.
Positive Factors
High gross margins
Sustained ~69% gross margins reflect durable product-level economics for biologic/tissue offerings. Strong gross margins provide a cushion to absorb demand shocks, support cash generation and R&D spend, and increase the chance of returning to operating profitability as volumes recover.
Negative Factors
Sharp revenue decline and downgraded guidance
A multiyear-scale decline in revenue and a materially reduced full-year outlook signal a meaningful loss of utilization and scale. Reduced revenue compresses fixed-cost absorption, strains operating leverage, limits reinvestment capacity and prolongs the timeline to normalized profitability and growth.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained ~69% gross margins reflect durable product-level economics for biologic/tissue offerings. Strong gross margins provide a cushion to absorb demand shocks, support cash generation and R&D spend, and increase the chance of returning to operating profitability as volumes recover.
Read all positive factors
Organogenesis Holdings (ORGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$313.97M
Dividend YieldN/A
Average Volume (3M)1.17M
Price to Earnings (P/E)―
Beta (1Y)1.70
Revenue Growth12.19%
EPS Growth1.97%
CountryUS
Employees869
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.15
Shares Outstanding128,674,550
10 Day Avg. Volume679,435
30 Day Avg. Volume1,174,366
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.51
Price to Sales (P/S)1.17
P/FCF Ratio-26.84
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue0.54
Enterprise Value/Gross Profit0.77
Enterprise Value/Ebitda7.50
Forecast
1Y Price Target
$3.00Price Target Upside-26.47% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.82
Revenue Forecast (FY)$282.87M
Organogenesis Holdings Business Overview & Revenue Model
Company Description
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its adva...
How the Company Makes Money
Organogenesis makes money primarily by selling its regenerative medicine products to healthcare providers and care sites (e.g., hospitals, outpatient wound clinics, physician offices, and ambulatory surgery centers) for use in wound healing and su...
Organogenesis Holdings Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Negative
The call detailed significant near-term financial deterioration driven by market disruption and policy-related clinician confusion: Q1 revenue fell 58% YoY, margins compressed sharply, and losses widened, prompting a material downgrade to full-year revenue guidance and a March restructuring. Offsetting these negatives are important strategic and clinical milestones — completion of a BLA submission for ReNu, a positive 170‑patient RCT for PuraPly AM, evidence of relative market share gains, disciplined cost reductions, and a solid cash position with no debt. While these highlights support longer-term confidence, they do not fully mitigate the severe short-term revenue and profitability declines and the uncertainty around CMS policy timing.Positive Updates
Completed BLA Submission for ReNu
On April 28 the company completed its BLA submission to the FDA for ReNu, a potential nonsurgical biologic for symptomatic knee osteoarthritis — a key regulatory milestone supporting future growth in a large unmet market.
Negative Updates
Severe Revenue Decline in Q1
Net product revenue for Q1 was $36.3M, down 58% year-over-year. Advanced Wound Care revenue declined 63% to $29.5M; Surgical & Sports Medicine revenue was $6.8M and flat year-over-year.
Read all updates
Q1-2026 Updates
Positive
Negative
Completed BLA Submission for ReNu
On April 28 the company completed its BLA submission to the FDA for ReNu, a potential nonsurgical biologic for symptomatic knee osteoarthritis — a key regulatory milestone supporting future growth in a large unmet market.
Read all positive updates
Company Guidance
Organogenesis updated 2026 net revenue guidance to $270 million–$310 million (a decline of ~45%–52% YoY vs prior guidance of a 25%–38% decline), now anticipating first‑half revenue declines of roughly 52%–49% YoY with sequential improvement thereafter and strong third‑ and fourth‑quarter growth but a more measured recovery overall; the company expects positive adjusted EBITDA generation in H2 and a return to more normalized profitability in Q4, plans to reduce operating expenses (ex‑COGS) ~25% YoY for 2026 (including >30% YoY in H2) and assumes ~$7 million of Q3–Q4 restructuring savings as part of an approximate $14 million annualized cost reduction from the March restructuring (88 employee reduction and St. Petersburg facility closure); these outlooks are framed against Q1 results of $36.3 million net product revenue (down 58% YoY), Advanced Wound Care $29.5M (down 63%), Surgical & Sports Medicine $6.8M (flat), an adjusted EBITDA loss of $48.2M, cash of $92.1M, no debt and $75M revolver availability, and reflect continued uncertainty from CMS commentary affecting utilization.Organogenesis Holdings Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
74
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 513.57M | 563.03M | 482.04M | 433.14M | 450.89M | 467.36M |
| Gross Profit | 361.62M | 425.51M | 366.30M | 326.66M | 345.87M | 353.16M |
| EBITDA | 37.30M | 73.91M | 15.76M | 36.03M | 40.32M | 87.00M |
| Net Income | -284.00K | 37.03M | 861.00K | 4.95M | 15.53M | 94.20M |
Balance Sheet | ||||||
| Total Assets | 519.99M | 598.73M | 497.89M | 460.02M | 449.36M | 443.26M |
| Cash, Cash Equivalents and Short-Term Investments | 92.10M | 93.68M | 135.57M | 104.34M | 102.48M | 113.93M |
| Total Debt | 70.86M | 132.84M | 43.31M | 119.35M | 123.79M | 132.30M |
| Total Liabilities | 138.65M | 164.81M | 112.57M | 181.36M | 183.69M | 201.92M |
| Stockholders Equity | 381.35M | 433.92M | 385.32M | 278.66M | 265.67M | 241.34M |
Cash Flow | ||||||
| Free Cash Flow | 17.08M | -24.46M | 4.18M | 6.55M | -9.04M | 30.76M |
| Operating Cash Flow | 30.75M | -10.31M | 14.21M | 30.92M | 24.86M | 61.98M |
| Investing Cash Flow | -13.67M | -14.15M | -10.03M | -24.36M | -33.90M | -31.22M |
| Financing Cash Flow | -35.52M | -17.36M | 27.64M | -5.50M | -2.20M | -1.04M |
Organogenesis Holdings Technical Analysis
Neutral
4.08
Price Trends
2.46
Negative
2.80
Negative
3.75
Negative
Market Momentum
-0.03
Positive
49.63
Neutral
31.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORGO, the sentiment is Neutral. The current price of 4.08 is above the 20-day moving average (MA) of 2.47, above the 50-day MA of 2.46, and above the 200-day MA of 3.75, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 49.63 is Neutral, neither overbought nor oversold. The STOCH value of 31.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ORGO.
Organogenesis Holdings Risk Analysis
Organogenesis Holdings disclosed 73 risk factors in its most recent earnings report. Organogenesis Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Organogenesis Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $412.77M | -48.28 | -1.59% | ― | -29.89% | 93.33% | |
57 Neutral | $436.62M | -9.95 | 174.92% | ― | 9.56% | 24.52% | |
56 Neutral | $309.85M | 15.28 | 10.62% | ― | -22.07% | -58.28% | |
54 Neutral | $811.73M | -106.66 | 1.99% | ― | 61.13% | 92.51% | |
54 Neutral | $369.63M | -47.58 | -1.00% | ― | 1.57% | 89.16% | |
52 Neutral | $313.97M | -1,097.97 | -0.07% | ― | 12.19% | 1.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ORGO
Organogenesis Holdings
2.44
-0.90
-26.95%
EBS
Emergent Biosolutions
8.00
1.48
22.70%
SIGA
SIGA Technologies
4.32
-1.15
-21.10%
ESPR
Esperion
3.15
2.11
202.88%
EOLS
Evolus
6.63
-2.75
-29.32%
SNDL
SNDL
1.42
0.18
14.52%
Organogenesis Holdings Corporate Events
Executive/Board ChangesShareholder Meetings
Organogenesis Stockholders Reelect Board and Approve Governance Items
Positive
Jun 16, 2026
On June 15, 2026, holders of Organogenesis Holdings’ Series A Convertible Preferred Stock voted by written consent to re-elect Garrett Lustig to the board of directors, extending his service until the next annual meeting and the qualificatio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.